Abstract: The present application relates to plasma cells and plasma cell precursors that express a macromolecule, such as a protein, protein mimetic or a peptide and compositions comprising these plasma cells or plasma cell precursors. The application further relates to methods of using and making the plasma cells and plasma cell precursors that express the macromolecule. Methods of treatment comprising administering the plasma cells or plasma cell precursors are also contemplated.

Abstract: Disclosed herein are pyrazole pyrimidine compounds that modulate and/or inhibit hematopoietic progenitor kinase 1, as well as methods of making such compounds and therapeutic methods of using same.

Abstract: Systems and methods are disclosed that provide smart alerts to users, e.g., alerts to users about diabetic states that are only provided when it makes sense to do so, e.g., when the system can predict or estimate that the user is not already cognitively aware of their current condition, e.g., particularly where the current condition is a diabetic state warranting attention. In this way, the alert or alarm is personalized and made particularly effective for that user. Such systems and methods still alert the user when action is necessary, e.g., a bolus or temporary basal rate change, or provide a response to a missed bolus or a need for correction, but do not alert when action is unnecessary, e.g., if the user is already estimated or predicted to be cognitively aware of the diabetic state warranting attention, or if corrective action was already taken.

Abstract: The present invention relates to compounds of the Formula (I), or a pharmaceutically acceptable salt, pharmaceutical preparation, or pharmaceutical composition thereof, and their use for the treatment of pain, inflammatory disease, neuropathy, dermatological disorders, pulmonary conditions, and cough, as well as inhibiting the Transient Receptor Potential A1 ion channel (TRPA1).

Abstract: The present invention relates to compounds of the Formula (I), or a pharmaceutically acceptable salt, pharmaceutical preparation, or pharmaceutical composition thereof, and their use for the treatment of pain, inflammatory disease, neuropathy, dermatological disorders, pulmonary conditions, and cough, as well as inhibiting the Transient Receptor Potential A1 ion channel (TRPA1).

Abstract: The present invention relates to compounds of the Formula (I), or a pharmaceutically acceptable salt, pharmaceutical preparation, or pharmaceutical composition thereof, and their use for the treatment of pain, inflammatory disease, neuropathy, dermatological disorders, pulmonary conditions, and cough, as well as inhibiting the Transient Receptor Potential A1 ion channel (TRPA1).

Abstract: This disclosure describes novel compounds and pharmaceutical compositions for inhibiting the TRPA1 ion channel and/or medical conditions related to TRPA1, such as pain and respiratory conditions.

Abstract: This disclosure describes novel compounds and pharmaceutical compositions for inhibiting the TRPA1 ion channel and/or medical conditions related to TRPA1, such as pain and respiratory conditions.

Abstract: A capacity control system for a variable capacity refrigerant compressor includes an internal bleed passage coupling a crankcase chamber of the compressor to a suction port, an electrically-operated two-port control valve that selectively opens and closes a passage between the crankcase chamber and a discharge chamber, and pressure sensors for measuring the compressor discharge pressure and suction pressure. A plunger of the control valve is disposed within the passage coupling the crankcase chamber and the discharge chamber, and a solenoid armature linearly positions the plunger within the passage to open and close the passage. The plunger has an axial bore that forms a continuous passage between the discharge chamber and a cavity in which the discharge pressure sensor is retained so that the sensor is continuously exposed to the discharge pressure regardless of the plunger position.

Abstract: A capacity control system for a variable capacity refrigerant compressor includes an internal bleed passage coupling a crankcase chamber of the compressor to a suction port, an electrically-operated two-port control valve that selectively opens and closes a passage between the crankcase chamber and a discharge chamber, and at least one pressure sensor within the control valve that is continuously coupled to the discharge chamber for measuring the compressor discharge pressure. A plunger of the control valve is disposed within the passage coupling the crankcase chamber and the discharge chamber, and a solenoid armature linearly positions the plunger within the passage to open and close the passage. The plunger has an axial bore that forms a continuous passage between the discharge chamber and a cavity in which the pressure sensor is retained so that the sensor is continuously exposed to the discharge pressure regardless of the plunger position.